Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 2/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCND2 | P30279 | 1/20 | 0.44 |
| ▸ | GALR2 | O43603 | 1/20 | 0.44 |
| ▸ | GALR1 | P47211 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449787 | 0.87 | ALK (0.54) | CCNA2CDK2CDK9ALKABL1 | |
| SCHEMBL13348309 | 0.87 | SYK (0.44) | ALKABL1BCRAXLEGFR | |
| SCHEMBL3448334 | 0.85 | ABL1 (0.46) | ALKABL1BCRJAK2AXL | |
| SCHEMBL3450288 | 0.84 | ABL1 (0.46) | ALKABL1BCRJAK2JAK1 | |
| SCHEMBL3449451 | 0.82 | AXL (0.57) | ALKAXLEGFR | |
| SCHEMBL3452720 | 0.81 | MAPK1 (0.51) | GALR2JAK3AXLSMN1; SMN2EGFR | |
| SCHEMBL3449764 | 0.81 | MAPK1 (0.51) | GALR2AXLSMN1; SMN2EGFR | |
| SCHEMBL3448492 | 0.80 | MALT1 (0.53) | JAK2JAK1TYK2MEN1KMT2A | |
| SCHEMBL3449638 | 0.80 | MAPK1 (0.50) | CCNA2CDK2GALR2JAK3AXL | |
| SCHEMBL3450023 | 0.80 | MAPK1 (0.50) | CCNA2CDK2GALR2JAK3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CCND3 1452/4885CCNK 2203/4885CCNA2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.